Key facts
| Recalling firm | Blaine Labs Inc |
|---|---|
| Manufacturer | Blaine Labs Inc. |
| Brand name | TERPENICOL |
| Product description | TERPENICOL Antifungal Cream (Undecylenic Acid 13%), 1.0 oz (28 g) bottles, Manufactured By: Blaine Labs, Inc., 11037 Lockport Place, Sante Fe Springs, CA 90670, NDC 63347-601-01. |
| Classification | Class II |
| Recall number | D-0695-2026 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry |
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of TERPENICOL Antifungal Cream (Undecylenic Acid 13%), 1.0 oz (28 g) bottles, Manufactured By: Blaine Labs, Inc., 11037 Lockport Place, Sante Fe Springs, CA 90670, NDC 63347-601-01. should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Blaine Labs Inc. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Blaine Labs Inc should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Blaine Labs Inc directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
Blaine Labs Inc’s FDA history
Argus HQ has recorded 8 total FDA actions tied to Blaine Labs Inc: 0 warning letters, 8 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Has Blaine Labs Inc had other FDA recalls or enforcement actions?
- Yes. Argus HQ has recorded 8 total FDA actions tied to Blaine Labs Inc, including 8 recalls and 0 warning letters.
- What is the FDA recall number for this event?
- FDA recall number D-0695-2026.
- What is the current status of this recall?
- Status as recorded by FDA: Ongoing.
- Where can I verify this recall directly with FDA?
- The verbatim FDA record is the source of truth for every recall Argus HQ tracks — always confirm against fda.gov before acting.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Blaine Labs Inc- Recall: Blaine Labs Inc — Class II recall: vite20 Antifungal Cream, (10% Undecylenic Acid), 0.54 OZ (15 g) bottle, Manufact… →
- Recall: Blaine Labs Inc — Class II recall: Fungal Fusion ERADICATION Solution, Antifungal & Antimicrobial Kit. Contains, 1x… →
- Recall: Blaine Labs Inc — Class II recall: TRIPENICOL S Antifungal Solution (Undecylenic Acid 25%), 1.25 FL OZ (37.5 mL) bo… →
- Recall: Blaine Labs Inc — Class I recall: Revitaderm Wound Care Gel, Benzalkonium Chloride 0.1%, packaged in 1.0 FL OZ (37… →
- Recall: Blaine Labs Inc — Class II recall: TERPENICOL Antifungal Solution, (Undecylenic (10-Undecenoic) acid 25%), 1.0 Fl O… →
- Recall: Blaine Labs Inc — Class II recall: TRIFLUENT PHARMA TRIDERGEL Wound Care Gel, (Benzalkonium Chloride 0.1%), 1.0 fl… →
- Recall: Blaine Labs Inc — Class II recall: Revitaderm Wound Care, First Aid Antiseptic Gel, Benzalkonium Chloride 0.1%) pac… →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Recall Database: Class II Recall: TERPENICOL by Blaine Labs Inc. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/blaine-labs-d-0695-2026-2026-07-08
"FDA Recall Database: Class II Recall: TERPENICOL by Blaine Labs Inc." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/recall/blaine-labs-d-0695-2026-2026-07-08.
Argus HQ Research. "FDA Recall Database: Class II Recall: TERPENICOL by Blaine Labs Inc." Digital Empire Holdings LLC. Accessed July 24, 2026. https://argushq.ai/recall/blaine-labs-d-0695-2026-2026-07-08.
@misc{argushq_argushq_ai_recall_blaine_labs_d_0695_2026_2026_07_08_2026,
title = {FDA Recall Database: Class II Recall: TERPENICOL by Blaine Labs Inc},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/blaine-labs-d-0695-2026-2026-07-08},
note = {Accessed: July 24, 2026}
}Source: FDA.gov — Recalls ↗

